Suven Life Sciences Ltd has secured patents in the US and New Zealand for one of its New Chemical Entities (NCE) for central nervous system therapy.

The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.

Histaminargic dysfunction has been strongly associated with the cognitive and behavioural deficits observed in several CNS disorders. H3 receptor blockade elevates acetylcholine in brain regions responsible for cognition, thus offering a means for targeting cognitive processes.